Cancer Communications
indexed by SCI
BMC

doi: 10.5732/cjc.010.10553
Targeted cancer therapies
Li Yan, Neal Rosen, Carlos Arteaga
US Chinese Anti-Cancer Association, USA. ynyinternational@yahoo.com.
[Abstract] With unprecedented understanding of molecular events underlying human cancer in this genomic era, a large number of drugs specifically targeting hypothesized oncogenic drivers to which tumors are potentially addicted to have been developed and continue to be developed. These targeted cancer therapies are being actively tested in clinical trials with mixed successes. This editorial provides an overview on successful targeted cancer drugs on the market and those drugs that are in late clinical development stages. Importantly, the article lays out main challenges in developing molecular targeted therapies and potential path forward to overcome these challenges, as well as opportunities for China in this new era of targeted agents. The editorial serves as an introduction to the Targeted Cancer Therapies series that will review in depth of major pathways and drugs targeting these pathways to be published in the coming issues of the Chinese Journal of Cancer.
Chinese Journal of Cancer 2011, Volume: 30, Issue 1, Page: 1-4
[ PDF Full-text ]
[Google Scholar]


Cite this article

Li Yan, Neal Rosen, Carlos Arteaga. Targeted cancer therapies. Chin J Cancer. 2011, 30(1):1-4. doi:10.5732/cjc.010.10553


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China